Quantum BioPharma Corp (QNTM): Broker Consensus Forecast
Quantum BioPharma Ltd (QNTM) relies on patent protection for biotechs and cannabinoids under strict FDA oversight, while the fragmentation of small assets creates inefficiency risks. This price chart captures the metric at 8.03. Financial stability is absent, as the company generates no regular income and is entirely dependent on external financing until it receives marketing authorizations for its drugs.
Analytical breakdowns for Quantum BioPharma Limited (QNTM)
- market value and analyst target forecast:
- stock exchange capitalization data:
- business book valuation details:
- business debt structure and liquidity details:
Aggregate Debt to Equity Quantum BioPharma Ltd|QNTM - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Quantum BioPharma Corp|QNTM - Company Aggregate Debts|Debts to Book Capitalization Quantum BioPharma Limited|QNTM - Company Long-Term Debt|Company Short-Term Loans and Borrowings Quantum BioPharma|Quick Liquidity Indicator quantumbiopharma.com
- earnings and market ratios statistics:
QNTM - Net Profit|Projected Future Earnings Quantum BioPharma Ltd|QNTM - Price to Earnings Ratio|Future Price to Earnings Multiple Quantum BioPharma Ltd.|QNTM - Price/Earnings to Growth Ratio|Company Value to EBITDA Quantum BioPharma Limited|QNTM - Operating profit before deduction of amortization|Earnings per share for the last four quarters Quantum BioPharma|QNTM - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months quantumbiopharma.com|QNTM - Earnings growth in current year|Expected net earnings per share growth next year Quantum BioPharma Ltd
General company analysis:QNTM quantumbiopharma.com
This indicator determines the weighted average fair value of the asset by measuring the gap between market quotes and the estimated growth potential according to experts. By analyzing the consensus share price based on forecasts, the investor assesses the undervaluation of Quantum BioPharma Ltd (QNTM), which in this case is based on the monetization of unique patents in the fields of neuroscience and cannabinoids for long-term profit extraction.
Competitors of Quantum BioPharma Ltd
haleon.com (HLN) - Analyst Target Range|Price Target Chart Kenvue KVUE|VRNA: Broker Consensus Forecast|MENS: Consensus Target|Ligand Corp - Analyst Forecast Prices|Amneal Pharmaceuticals (AMRX) - Price Target Chart|Consensus Target perrigo.com|Price Target Chart Alvotech SA|Liquidia Corp - Forecast Levels Chart|Analyst Consensus Forecast GLPG|ANIP (ANI Pharmaceuticals Corp) - Fair Value Consensus|Analyst Consensus Forecast MNKD (MannKind Corporation)|Analyst Consensus Forecast amphastar.com AMPH|PCRX - Price Target Chart|Fair Value Consensus SPRY (ARS Pharmaceuticals Inc)|Theravance (TBPH) - Price Target Chart|Consensus Target Aquestive Corp|SCPH (scPharmaceuticals, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Tectonic|Consensus Target TNXP (Tonix Pharmaceuticals Holding Corp.)|SXTC (sxtchina.com) - Fair Value Consensus|Price Target Chart Eupraxia Pharmaceuticals Inc. EPRX|BioHarvest Sciences Inc (BHST) - Average Forecast Price|EXOZ: Consensus Target|Oramed Pharmaceuticals - Analyst Forecast Prices|ENTX: Analyst Consensus Forecast|MindWalk Holdings, Inc. - Fair Value Consensus|ABVC (ABVC BioPharma Inc) - Analyst Consensus Forecast|Average Forecast Price Cumberland Corp CPIX|Price Target Chart FibroGen, Inc. (FGEN)|TELO (telomirpharma.com) - Fair Value Consensus|Price Target Chart Rani Therapeutics Holdings, Inc. RANI|Analyst Target Range Synergy CHC Corp.|RLYB: Consensus Target|LEXX - Analyst Consensus Forecast|PULM: Analyst Consensus Forecast|Pheton Holdings (PTHL) - Analyst Consensus Forecast|Price Target Chart Aptorum Group Ltd|Broker Consensus Forecast LYRA (Lyra Therapeutics Inc.)|Consensus Target IBO (Impact BioMedical Inc)|Analyst Forecast Prices TNFA|cbdMD - Consensus Target|Analyst Consensus Forecast painreform.com PRFX|CYTO - Price Target Chart|Lipella Pharmaceuticals Inc (LIPO) - Consensus Target|OPTN (Optinose) - Consensus Target|Pieris Pharma - Fair Value Consensus|PROC (Procaps Group S.A.) - Analyst Consensus Forecast|Price Target Chart PTPI|Analyst Consensus Forecast QLI|Analyst Median Target Acelyrin Inc.|Price Target Chart TFF Pharma TFFP
